Docetaxel in the treatment of non-small cell lung carcinoma: An update and analysis

Lung Cancer: Targets and Therapy

Volumn 1, Issue , 2010, Pages 63-76

  Gubens, Matthew A ^a   Wakelee, Heather A ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adjuvant; Docetaxel; Metastatic; Non small cell lung carcinoma; Review; Taxanes

Indexed keywords

5 (4 BROMO 2 CHLOROANILINO) 4 FLUORO 1 METHYL 1H BENZIMIDAZOLE 6 CARBOHYDROXAMIC ACID 2 HYDROXYETHYL ESTER; ANTICONVULSIVE AGENT; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; BORTEZOMIB; CAPECITABINE; CARBOPLATIN; CETUXIMAB; CISPLATIN; DEXAMETHASONE; DOCETAXEL; GEFITINIB; GEMCITABINE; IFOSFAMIDE; KETOCONAZOLE; MITOMYCIN; NAVELBINE; NIMOTUZUMAB; PACLITAXEL; PACLITAXEL POLIGLUMEX; PLACEBO; PLATINUM DERIVATIVE; POLYSORBATE 80; SUNITINIB; TAXANE DERIVATIVE; TOPOTECAN; UNINDEXED DRUG; VANDETANIB; VINBLASTINE; VINDESINE;

ALOPECIA; ANEMIA; ASTHENIA; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER SURVIVAL; CELL CYCLE ARREST; CELL DEATH; CLINICAL TRIAL; DIARRHEA; DRUG CLEARANCE; DRUG EFFICACY; DRUG EXCRETION; DRUG MECHANISM; DYSESTHESIA; ESOPHAGITIS; FATIGUE; FEBRILE NEUTROPENIA; HUMAN; HYPERSENSITIVITY REACTION; INTERSTITIAL PNEUMONIA; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MICROTUBULE ASSEMBLY; MULTIPLE CYCLE TREATMENT; NAIL DYSTROPHY; NAUSEA; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; PARESTHESIA; PATIENT SELECTION; PERIPHERAL EDEMA; PNEUMONIA; PREDICTION; QUALITY OF LIFE; REVIEW; STOMATITIS; VOMITING;

EID: 77955160104     PISSN: None     EISSN: 11792728     Source Type: Journal    
DOI: None     Document Type: Review

References (75)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin. 2009;59(4):225-249.
2. Molina JR, Yang P, Cassivi SD, et al. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc. 2008;83(5):584-594.
3. Cortes JE, Pazdur R, Cortes JE, Pazdur R. Docetaxel. J Clin Oncol. 1995;13(10):2643-2655.
4. Verweij J, Clavel M, Chevalier B. Paclitaxel (Taxol) and docetaxel (Taxotere): not simply two of a kind. Ann Oncol. 1994;5(6):495-505.
5. Montero A, Fossella F, Hortobagyi G, et al. Docetaxel for treatment of solid tumours: a systematic review of clinical data. Lancet Oncol. 2005;6(4):229-239.
6. Fossella FV, DeVore R, Kerr RN, et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. [erratum appears in J Clin Oncol. 2004;22(1):209]. J Clin Oncol. 2000;18(12):2354-2362.
7. Herbst RS, Khuri FR, Herbst RS, Khuri FR. Mode of action of docetaxel - a basis for combination with novel anticancer agents. Cancer Treat Rev. 2003;29(5):407-415.
8. Fitzpatrick FA, Wheeler R, Fitzpatrick FA, Wheeler R. The immunopharmacology of paclitaxel (Taxol), docetaxel (Tax-otere), and related agents. Int Immunopharmacol. 2003;3(13-14): 1699-1714.
9. Wailoo A, Sutton A, Morgan A, Wailoo A, Sutton A, Morgan A. The risk of febrile neutropenia in patients with non-small-cell lung cancer treated with docetaxel: a systematic review and meta-analysis. Br J Cancer. 2009;100(3):436-441.
10. Di Maio M, Perrone F, Chiodini P, et al. Individual patient data meta-analysis of docetaxel administered once every 3 weeks compared with once every week second-line treatment of advanced non-small-cell lung cancer. J Clin Oncol. 2007;25(11):1377-1382.
11. Kintzel PE, Michaud LB, Lange MK, Kintzel PE, Michaud LB, Lange MK. Docetaxel-associated epiphora. Pharmacotherapy. 2006;26(6):853-867.
12. Engels FK, Mathot RA, Verweij J, Engels FK, Mathot RAA, Verweij J. Alternative drug formulations of docetaxel: a review. Anti Cancer Drugs. 2007;18(2):95-103.
13. Grande C, Villanueva MJ, Huidobro G, et al. Docetaxel-induced inter-stitial pneumonitis following non-small-cell lung cancer treatment. Clin Transl Oncol. 2007;9(9):578-581.
14. Nicolopoulos J, Howard A, Nicolopoulos J, Howard A. Docetaxel-induced nail dystrophy. Aust J Derm. 2002;43(4):293-296.
15. Baker SD, Sparreboom A, Verweij J, Baker SD, Sparreboom A, Verweij J. Clinical pharmacokinetics of docetaxel: recent developments. Clin Pharmacokinet. 2006;45(3):235-252.
16. Clarke SJ, Rivory LP, Clarke SJ, Rivory LP. Clinical pharmacokinetics of docetaxel. Clin Pharmacokinet. 1999;36(2):99-114.
17. Azzoli CG, Baker SD, Temin S, et al. American Society of Clinical Oncology clinical practice guideline update on chemotherapy for stage iv non-small-cell lung cancer. J Clin Oncol. 2009;27(36): 6251-6266.
18. Roszkowski K, Pluzanska A, Krzakowski M, et al. A multicenter, ran-domized, phase III study of docetaxel plus best supportive care versus best supportive care in chemotherapy-naive patients with metastatic or non-resectable localized non-small cell lung cancer (NSCLC). Lung Cancer. 2000;27(3):145-157.
19. Kudoh S, Takeda K, Nakagawa K, et al. Phase III study of docetaxel compared with vinorelbine in elderly patients with advanced non-small-cell lung cancer: results of the West Japan Thoracic Oncology Group Trial (WJTOG 9904). J Clin Oncol. 2006;24(22):3657-3663.
20. Georgoulias V, Ardavanis A, Agelidou A, et al. Docetaxel versus docetaxel plus cisplatin as front-line treatment of patients with advanced non-small-cell lung cancer: a randomized, multicenter phase III trial. J Clin Oncol. 2004;22(13):2602-2609.
21. Fossella F, Pereira JR, von Pawel J, et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol. 2003;21(16):3016-3024.
22. Belani CP, Fossella F, Belani CP, Fossella F. Elderly subgroup analysis of a randomized phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for first-line treatment of advanced nonsmall cell lung carcinoma (TAX 326). Cancer. 2005;104(12):2766-2774.
23. Kubota K, Watanabe K, Kunitoh H, et al. Phase III randomized trial of docetaxel plus cisplatin versus vindesine plus cisplatin in patients with stage IV non-small-cell lung cancer: the Japanese Taxotere Lung Cancer Study Group. J Clin Oncol. 2004;22(2):254-261.
24. Tan EH, Rolski J, Grodzki T, et al. Global Lung Oncology Branch trial 3 (GLOB3): final results of a randomised multinational phase III study alternating oral and i.v. vinorelbine plus cisplatin versus docetaxel plus cisplatin as first-line treatment of advanced non-small-cell lung cancer. Ann Oncol. 2009;20(7):1249-1256.
25. Booton R, Lorigan P, Anderson H, et al. A phase III trial of docetaxel/ carboplatin versus mitomycin C/ifosfamide/cisplatin (MIC) or mitomycin C/vinblastine/cisplatin (MVP) in patients with advanced non-small-cell lung cancer: a randomised multicentre trial of the British Thoracic Oncology Group (BTOG1). Ann Oncol. 2006;17(7): 1111-1119.
26. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002;346(2):92-98.
27. Yoshimura N, Kudoh S, Kimura T, et al. Phase II study of docetaxel and carboplatin in elderly patients with advanced non-small cell lung cancer. J Thoracic Oncol. 2009;4(3):371-375.
28. Han K, Cao W, Che J, et al. First line chemotherapy with weekly docetaxel and cisplatin in elderly patients with advanced non-small cell lung cancer: a multicenter phase II study. J Thoracic Oncol. 2009;4(4):512-517.
29. Ohe Y, Niho S, Kakinuma R, et al. A phase II study of cisplatin and docetaxel administered as three consecutive weekly infusions for advanced non-small-cell lung cancer in elderly patients. Ann Oncol. 2004;15(1):45-50.
30. Miller AA, Wang XF, Gu L, et al. Phase II randomized study of dose-dense docetaxel and cisplatin every 2 weeks with pegfilgrastim and darbepoetin alfa with and without the chemoprotector BNP7787 in patients with advanced non-small cell lung cancer (CALGB 30303). J Thoracic Oncol. 2008;3(10):1159-1165.
31. Kubota K, Kawahara M, Ogawara M, et al. Vinorelbine plus gemcitabine followed by docetaxel versus carboplatin plus paclitaxel in patients with advanced non-small-cell lung cancer: a randomised, open-label, phase III study.[see comment]. Lancet Oncol. 2008;9(12): 1135-1142.
32. Georgoulias V, Ardavanis A, Tsiafaki X, et al. Vinorelbine plus cisplatin versus docetaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III randomized trial. J Clin Oncol. 2005;23(13): 2937-2945.
33. Pujol JL, Breton JL, Gervais R, et al. Gemcitabine-docetaxel versus cisplatin-vinorelbine in advanced or metastatic non-small-cell lung cancer: a phase III study addressing the case for cisplatin. Ann Oncol. 2005;16(4):602-610.
34. Georgoulias V, Androulakis N, Kotsakis A, et al. Docetaxel versus docetaxel plus gemcitabine as front-line treatment of patients with advanced non-small cell lung cancer: a randomized, multicenter phase III trial. Lung Cancer. 2008;59(1):57-63.
35. Hainsworth JD, Spigel DR, Farley C, et al. Weekly docetaxel versus docetaxel/gemcitabine in the treatment of elderly or poor performance status patients with advanced nonsmall cell lung cancer: a randomized phase 3 trial of the Minnie Pearl Cancer Research Network. Cancer. 2007;110(9):2027-2034.
36. Cobo M, Isla D, Massuti B, et al. Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer. J Clin Oncol. 2007;25(19):2747-2754.
37. Rosell R, Perez-Roca L, Sanchez JJ, et al. Customized treatment in non-small-cell lung cancer based on EGFR mutations and BRCA1 mRNA expression. PLoS One. 2009;4(5):e5133.
38. Belani CP, Schreeder MT, Steis RG, et al. Cetuximab in combination with carboplatin and docetaxel for patients with metastatic or advanced-stage nonsmall cell lung cancer: a multicenter phase 2 study. Cancer. 2008;113(9):2512-2517.
39. Lynch T, Patel T, Dreisbach L, et al. A randomized multicenter phase III study of cetuximab (ErbituxR) in combination with taxane/carboplatin versus taxane/carboplatin alone as first-line treatment for patients with advanced/metastatic non-small cell lung cancer (NSCLC): BMS 099. Paper presented at: IASLC World Conference on Lung Cancer, 2007; Seoul.
40. Lilenbaum R, Wang X, Gu L, et al. Randomized phase II trial of docetaxel plus cetuximab or docetaxel plus bortezomib in patients with advanced non-small-cell lung cancer and a performance status of 2: CALGB 30402. J Clin Oncol. 2009;27(27):4487-4491.
41. Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol. 2000;18(10):2095-2103.
42. Shepherd FA, Fossella FV, Lynch T, et al. Docetaxel (Taxotere) shows survival and quality-of-life benefits in the second-line treatment of non-small cell lung cancer: a review of two phase III trials. Semin Oncol. 2001;28(1 Suppl 2):4-9.
43. Ramlau R, Gervais R, Krzakowski M, et al. Phase III study comparing oral topotecan to intravenous docetaxel in patients with pretreated advanced non-small-cell lung cancer. J Clin Oncol. 2006;24(18): 2800-2807.
44. Hann CL, Brahmer JR, Hann CL, Brahmer JR. Second-line therapy for advanced non-small-cell lung cancer. Curr Oncol Rep. 2006;8(4): 243-247.
45. Paz-Ares L, Ross H, O'Brien M, et al. Phase III trial comparing paclitaxel poliglumex vs docetaxel in the second-line treatment of non-small-cell lung cancer. Br J Cancer. 2008;98(10): 1608-1613.
46. Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol. 2004;22(9):1589-1597.
47. Camps C, Massuti B, Jimenez A, et al. Randomized phase III study of 3-weekly versus weekly docetaxel in pretreated advanced non-small-cell lung cancer: a Spanish Lung Cancer Group trial. Ann Oncol. 2006;17(3):467-472.
48. Gridelli C, Gallo C, Di Maio M, et al. A randomised clinical trial of two docetaxel regimens (weekly vs 3 week) in the second-line treatment of non-small-cell lung cancer. The DISTAL 01 study. Br J Cancer. 2004;91(12):1996-2004.
49. Schuette W, Nagel S, Blankenburg T, et al. Phase III study of second-line chemotherapy for advanced non-small-cell lung cancer with weekly compared with 3-weekly docetaxel. J Clin Oncol. 2005;23(33): 8389-8395.
50. Kim ES, Hirsh V, Mok T, et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet. 2008;372(9652):1809-1818.
51. Maruyama R, Nishiwaki Y, Tamura T, et al. Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer. J Clin Oncol. 2008;26(26): 4244-4252.
52. Stinchcombe TE, Buzkova P, Choksi J, et al. A phase I/II trial of weekly docetaxel and gefitinib in elderly patients with stage IIIB/IV non-small cell lung cancer. Lung Cancer. 2006;52(3):305-311.
53. Takeda K, Negoro S, Tamura T, et al. Phase III trial of docetaxel plus gemcitabine versus docetaxel in second-line treatment for non-small-cell lung cancer: results of a Japan Clinical Oncology Group trial (JCOG0104). Ann Oncol. 2009;20(5):835-841.
54. Gebbia V, Gridelli C, Verusio C, et al. Weekly docetaxel vs docetaxel-based combination chemotherapy as second-line treatment of advanced non-small-cell lung cancer patients. The DISTAL-2 randomized trial. Lung Cancer. 2009;63(2):251-258.
55. Schneider BJ, Kalemkerian GP, Kraut MJ, et al. Phase II study of celecoxib and docetaxel in non-small cell lung cancer (NSCLC) patients with progression after platinum-based therapy. J Thoracic Oncol. 2008;3(12):1454-1459.
56. Kim ES, Mauer AM, William WN Jr, et al. A phase 2 study of cetuximab in combination with docetaxel in chemotherapy-refractory/ resistant patients with advanced nonsmall cell lung cancer. Cancer. 2009;115(8):1713-1722.
57. Heymach JV, Johnson BE, Prager D, et al. Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer. [erratum appears in J Clin Oncol. 2008;26(1):165-166]. J Clin Oncol. 2007;25(27):4270-4277.
58. Herbst RS, Sun Y, Korfee S, et al. Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small cell lung cancer (NSCLC): A randomized, double-bline phase III trial (ZODIAC). J Clin Oncol. 2009;27(Suppl 18):CRA8003.
59. Fidias PM, Dakhil SR, Lyss AP, et al. Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer. J Clin Oncol. 2009;27(4):591-598.
60. Scagliotti GV, Douillard JY, Scagliotti GV, Douillard JY. Docetaxel in combined-modality treatment of inoperable locally or regionally advanced lung cancer. Lung Cancer. 2004;46(Suppl 2):S13-S21.
61. Gandara DR, Chansky K, Albain KS, et al. Long-term survival with concurrent chemoradiation therapy followed by consolidation docetaxel in stage IIIB non-small-cell lung cancer: a phase II Southwest Oncology Group Study (S9504). Clin Lung Cancer. 2006;8(2): 116-121.
62. Kelly K, Chansky K, Gaspar LE, et al. Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023. J Clin Oncol. 2008;26(15):2450-2456.
63. Hanna N, Neubauer M, Yiannoutsos C, et al. Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier Oncology Group and US Oncology. J Clin Oncol. 2008;26(35):5755-5760.
64. Kiura K, Takigawa N, Segawa Y, et al. Randomized phase III trial of docetaxel and cisplatin combination chemotherapy versus mitomycin, vindesine, and cisplatin combination chemotherapy with concurrent thoracic radiation therapy for locally advanced non-small-cell lung can-cer: OLCSG 0007. J Clin Oncol (Meeting Abstracts). 2008;26:7515.
65. Scagliotti GV, Szczesna A, Ramlau R, et al. Docetaxel-based induction therapy prior to radiotherapy with or without docetaxel for non-small-cell lung cancer. Br J Cancer. 2006;94(10):1375-1382.
66. Jain AK, Hughes RS, Sandler AB, et al. A phase II study of concurrent chemoradiation with weekly docetaxel, carboplatin, and radiation therapy followed by consolidation chemotherapy with docetaxel and carboplatin for locally advanced inoperable non-small cell lung cancer (NSCLC). J Thoracic Oncol. 2009;4(6): 722-727.
67. Mattson K, Abratt R, Ten GV, et al. Docetaxel as neo-adjuvant therapy for radically treatable stage III non-small cell lung cancer: early results of an international phase III study. Lung Cancer. 2001;34(Suppl 4): S21-S23.
68. Mattson KV, Abratt RP, ten Velde G, et al. Docetaxel as neoadjuvant therapy for radically treatable stage III non-small-cell lung cancer: a multinational randomised phase III study. Ann Oncol. 2003;14(1): 116-122.
69. Betticher DC, Rosell R. Neoadjuvant treatment of early-stage resectable non-small-cell lung cancer. Lung Cancer. 2004;46(Suppl 2):S23-S32.
70. Kunitoh H, Kato H, Tsuboi M, et al. A randomised phase II trial of preoperative chemotherapy of cisplatin-docetaxel or docetaxel alone for clinical stage IB/II non-small-cell lung cancer results of a Japan Clinical Oncology Group trial (JCOG 0204). Br J Cancer. 2008;99(6): 852-857.
71. Kawamura M, Eguchi K, Izumi Y, et al. Phase II trial of gemcitabine and docetaxel in patients with completely resected stage IIA-IIIA non-small-cell lung cancer. Cancer Chemother Pharmacol. 2007;60(4): 495-501.
72. Stinchcombe TE, Harper HD, Hensing TA, et al. The feasibility of adjuvant carboplatin and docetaxel in patients with curatively resected non-small cell lung cancer. J Thoracic Oncol. 2008;3(2):145-151.
73. Azzoli CG, Krug LM, Miller VA, et al. A phase II tolerability study of cisplatin plus docetaxel as adjuvant chemotherapy for resected non-small cell lung cancer. J Thoracic Oncol. 2007;2(7):638-644.
74. Gralla RJ, Griesinger F. Interpreting clinical trials in lung cancer: impact of methodology and endpoints. J Thorac Oncol. 2007;2(Suppl 2): S51-S58.
75. Dancey J, Shepherd FA, Gralla RJ, et al. Quality of life assessment of second-line docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: results of a prospective, randomized phase III trial. Lung Cancer. 2004;43(2):183-194.